Jump to content

TREAT-NMD: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Undid revision 845825934 by Boghog (talk) far as I can see, referencing WAS consistent, revert unnecessary edit; some cleanup
what was inconsistent was the formatting of first names, Vancouver style formatting insures a consistent format, CS1 does not; it is inefficient to use first1, last1, ... parameters if only the first name initials are used; restored other edits that were useful: removed redundant PMC prefixes and URLs from citations with DOIs; restored refbegin/refend templates
Line 16: Line 16:
| website = {{url|http://www.treat-nmd.eu}}
| website = {{url|http://www.treat-nmd.eu}}
}}
}}
'''TREAT-NMD''' is a global academic network that focuses on advancing research in [[Neuromuscular disease |neuromuscular disorders]].<ref>{{Cite journal |last=Leary |first=Rebecca |last2=Oyewole |first2=Anne |last3=Bushby |first3=Katharine |last4=Aartsma-Rus |first4=Annemieke |date=2017-07-06 |title=Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD) |url=http://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1604110 |journal=Neuropediatrics |language=en |volume=48 |issue=04 |pages=211–220 |doi=10.1055/s-0037-1604110 |issn=0174-304X}}</ref> It was established in 2007 with its coordination centre at the [[Newcastle University]].<ref>{{Cite journal |last=Bushby |first=K. |last2=Lynn |first2=S. |last3=Straub |first3=T. |last4=TREAT-NMD Network |date=2009 |title=Collaborating to bring new therapies to the patient--the TREAT-NMD model |url=https://www.ncbi.nlm.nih.gov/pubmed/19772190 |journal=Acta Myologica: Myopathies and Cardiomyopathies: Official Journal of the Mediterranean Society of Myology |volume=28 |issue=1 |pages=12–15 |issn=1128-2460 |pmc=PMC2859629 |pmid=19772190}}</ref> As of 2018, the network comprises of over a hundred research centres and patient organisations from 54 countries<ref>{{Cite web |url=http://www.treat-nmd.eu/about/membership/organizations/ |title=TREAT-NMD Alliance Members – Organizations |last= |first= |date= |website=www.treat-nmd.eu |access-date=2018-06-13}}</ref> as well as independent academics and patient representatives.<ref>{{Cite web |url=http://www.treat-nmd.eu/about/membership/individuals/ |title=TREAT-NMD Alliance Members – Individuals |last= |first= |date= |website=www.treat-nmd.eu |access-date=2018-06-13}}</ref> The network's aim is to provide infrastructure to accelerating research through supporting collaboration between its members.<ref>{{Cite web |url=http://www.treat-nmd.eu/about/network/about-network/ |title=TREAT-NMD : About the TREAT-NMD network |website=www.treat-nmd.eu |language=en |access-date=2018-06-13}}</ref> Its main goals include improving trial-readiness worldwide, advancing patient diagnosis and care and accelerating pre-clinical research.<ref>{{cite journal |last1=Willmann |first1=R. |last2=Rüegg |first2=M.A. |last3=Fairclough |first3=R. |last4=Davies |first4=K.E. |last5=Possekel |first5=S. |last6=Meier |first6=T. |title=T.P.3.03 TREAT-NMD-Activity 7: Accelerate preclinical phase of new therapeutic treatment development |journal=Neuromuscular Disorders |date=October 2008 |volume=18 |issue=9-10 |pages=794 |doi=10.1016/j.nmd.2008.06.242 |format=Conference abstract}}</ref><ref>{{cite journal |last1=Mercuri |first1=E. |last2=Mayhew |first2=A. |last3=Muntoni |first3=F. |last4=Messina |first4=S. |last5=Straub |first5=V. |last6=Van Ommen |first6=G.J. |last7=Voit |first7=T. |last8=Bertini |first8=E. |last9=Bushby |first9=K. |title=Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; Report of three expert workshops: TREAT-NMD/ENMC Workshop on outcome measures, 12th–13th May 2007, Naarden, The Netherlands; TREAT-NMD Workshop on outcome measures in experimental trials for DMD, 30th June–1st July 2007, Naarden, The Netherlands; Conjoint Institute of Myology TREAT-NMD Meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France |journal=Neuromuscular Disorders |date=November 2008 |volume=18 |issue=11 |pages=894–903 |doi=10.1016/j.nmd.2008.07.003 |format=Workshop report}}</ref>
'''TREAT-NMD''' is a global academic network that focuses on advancing research in [[Neuromuscular disease |neuromuscular disorders]].<ref>{{Cite journal |last=Leary |first=Rebecca |last2=Oyewole |first2=Anne |last3=Bushby |first3=Katharine |last4=Aartsma-Rus |first4=Annemieke | name-list-format = vanc |date=2017-07-06 |title=Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD) |journal=Neuropediatrics |volume=48 |issue=04 |pages=211–220 |doi=10.1055/s-0037-1604110 |issn=0174-304X}}</ref> It was established in 2007 with its coordination centre at the [[Newcastle University]].<ref>{{cite journal | vauthors = Bushby K, Lynn S, Straub T | title = Collaborating to bring new therapies to the patient--the TREAT-NMD model | journal = Acta Myologica | volume = 28 | issue = 1 | pages = 12–5 | date = July 2009 | pmid = 19772190 | pmc = 2859629 }}</ref> As of 2018, the network comprises of over a hundred research centres and patient organisations from 54 countries<ref>{{cite web |url=http://www.treat-nmd.eu/about/membership/organizations/ |title=TREAT-NMD Alliance Members – Organizations |last= |first= |date= |website=www.treat-nmd.eu |access-date=2018-06-13}}</ref> as well as independent academics and patient representatives.<ref>{{Cite web |url=http://www.treat-nmd.eu/about/membership/individuals/ |title=TREAT-NMD Alliance Members – Individuals |website=www.treat-nmd.eu |access-date=2018-06-13}}</ref> The network's aim is to provide infrastructure to accelerating research through supporting collaboration between its members.<ref>{{Cite web |url=http://www.treat-nmd.eu/about/network/about-network/ |title=TREAT-NMD : About the TREAT-NMD network |website=www.treat-nmd.eu }}</ref> Its main goals include improving trial-readiness worldwide, advancing patient diagnosis and care and accelerating pre-clinical research.<ref>{{cite journal | vauthors = Willmann R, Rüegg MA, Fairclough R, Davies KE, Possekel S, Meier T |title=T.P.3.03 TREAT-NMD-Activity 7: Accelerate preclinical phase of new therapeutic treatment development |journal=Neuromuscular Disorders |date=October 2008 |volume=18 |issue=9-10 |pages=794 |doi=10.1016/j.nmd.2008.06.242 |format=Conference abstract}}</ref><ref>{{cite journal | vauthors = Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ, Voit T, Bertini E, Bushby K | display-authors = 6 | title = Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th--13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June--1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France | journal = Neuromuscular Disorders | volume = 18 | issue = 11 | pages = 894–903 | date = November 2008 | pmid = 18818076 | doi = 10.1016/j.nmd.2008.07.003 | format = Workshop report }}</ref>


==References==
==References==
Line 22: Line 22:


==Further reading==
==Further reading==
{{refbegin}}
*{{Cite journal |last=Heslop |first=Emma |last2=Csimma |first2=Cristina |last3=Straub |first3=Volker |last4=McCall |first4=John |last5=Nagaraju |first5=Kanneboyina |last6=Wagner |first6=Kathryn R. |last7=Caizergues |first7=Didier |last8=Korinthenberg |first8=Rudolf |last9=Flanigan |first9=Kevin M. |date=2015-04-23 |title=The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development |url=https://doi.org/10.1186/s13023-015-0258-1 |journal=Orphanet Journal of Rare Diseases |volume=10 |issue=1 |pages=49 |doi=10.1186/s13023-015-0258-1 |issn=1750-1172 |pmc=PMC4417237 |pmid=25902795}}
*{{Cite journal |last=Bladen |first=Catherine L. |last2=Rafferty |first2=Karen |last3=Straub |first3=Volker |last4=Monges |first4=Soledad |last5=Moresco |first5=Angélica |last6=Dawkins |first6=Hugh |last7=Roy |first7=Anna |last8=Chamova |first8=Teodora |last9=Guergueltcheva |first9=Velina |date=2013-08-26 |title=The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia |url=https://doi.org/10.1002/humu.22390 |journal=Human Mutation |language=en |volume=34 |issue=11 |pages=1449–1457 |doi=10.1002/humu.22390 |issn=1059-7794}}
*{{Cite journal |last=Heslop |first=Emma |last2=Csimma |first2=Cristina |last3=Straub |first3=Volker |last4=McCall |first4=John |last5=Nagaraju |first5=Kanneboyina |last6=Wagner |first6=Kathryn R. |last7=Caizergues |first7=Didier |last8=Korinthenberg |first8=Rudolf |last9=Flanigan |first9=Kevin M. | name-list-format = vanc | display-authors = 6 |date=2015-04-23 |title=The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development |journal=Orphanet Journal of Rare Diseases |volume=10 |issue=1 |pages=49 |doi=10.1186/s13023-015-0258-1 |pmc= 4417237 |pmid=25902795}}
*{{Cite journal |last=Bladen |first=Catherine L. |last2=Rafferty |first2=Karen |last3=Straub |first3=Volker |last4=Monges |first4=Soledad |last5=Moresco |first5=Angélica |last6=Dawkins |first6=Hugh |last7=Roy |first7=Anna |last8=Chamova |first8=Teodora |last9=Guergueltcheva |first9=Velina | name-list-format = vanc | display-authors = 6 |date=2013-08-26 |title=The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia |journal=Human Mutation |volume=34 |issue=11 |pages=1449–1457 |doi=10.1002/humu.22390 }}
*{{Cite journal |last=Aartsma-Rus |first=Annemieke |last2=Mercuri |first2=Eugenio |last3=Vroom |first3=Elizabeth |last4=Balabanov |first4=Pavel |date=2018 |title=Meeting report of the “Regulatory Exchange Matters” session at the 5th International TREAT-NMD Conference: |url=http://linkinghub.elsevier.com/retrieve/pii/S0960896618301962 |journal=Neuromuscular Disorders |doi=10.1016/j.nmd.2018.04.009 |issn=0960-8966}}
*{{Cite journal |last=Aartsma-Rus |first=Annemieke |last2=Mercuri |first2=Eugenio |last3=Vroom |first3=Elizabeth |last4=Balabanov |first4=Pavel | name-list-format = vanc |date=2018 |title=Meeting report of the “Regulatory Exchange Matters” session at the 5th International TREAT-NMD Conference: |journal=Neuromuscular Disorders |doi=10.1016/j.nmd.2018.04.009 |issn=0960-8966}}

{{refend}}
[[Category:Research organizations]]
[[Category:Research organizations]]

Revision as of 16:59, 14 June 2018

TREAT-NMD
Translational Research in Europe - Assessment and Treatment of Neuromuscular diseases
KeywordsNeuromuscular diseases, clinical research
Project typeNetwork of Excellence
Funding agencyEuropean Commission
ReferenceFP6-036825
ObjectiveImproving trial-readiness worldwide, advancing patient diagnosis and care and accelerating pre-clinical research
Project coordinatorNewcastle University
ParticipantsUniversities, pharmaceutical companies, patient organisations
Websitewww.treat-nmd.eu

TREAT-NMD is a global academic network that focuses on advancing research in neuromuscular disorders.[1] It was established in 2007 with its coordination centre at the Newcastle University.[2] As of 2018, the network comprises of over a hundred research centres and patient organisations from 54 countries[3] as well as independent academics and patient representatives.[4] The network's aim is to provide infrastructure to accelerating research through supporting collaboration between its members.[5] Its main goals include improving trial-readiness worldwide, advancing patient diagnosis and care and accelerating pre-clinical research.[6][7]

References

  1. ^ Leary, Rebecca; Oyewole, Anne; Bushby, Katharine; Aartsma-Rus, Annemieke (2017-07-06). "Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD)". Neuropediatrics. 48 (04): 211–220. doi:10.1055/s-0037-1604110. ISSN 0174-304X. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
  2. ^ Bushby K, Lynn S, Straub T (July 2009). "Collaborating to bring new therapies to the patient--the TREAT-NMD model". Acta Myologica. 28 (1): 12–5. PMC 2859629. PMID 19772190.
  3. ^ "TREAT-NMD Alliance Members – Organizations". www.treat-nmd.eu. Retrieved 2018-06-13.
  4. ^ "TREAT-NMD Alliance Members – Individuals". www.treat-nmd.eu. Retrieved 2018-06-13.
  5. ^ "TREAT-NMD : About the TREAT-NMD network". www.treat-nmd.eu.
  6. ^ Willmann R, Rüegg MA, Fairclough R, Davies KE, Possekel S, Meier T (October 2008). "T.P.3.03 TREAT-NMD-Activity 7: Accelerate preclinical phase of new therapeutic treatment development". Neuromuscular Disorders. 18 (9–10): 794. doi:10.1016/j.nmd.2008.06.242. {{cite journal}}: |format= requires |url= (help)
  7. ^ Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ, et al. (November 2008). "Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th--13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June--1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France". Neuromuscular Disorders. 18 (11): 894–903. doi:10.1016/j.nmd.2008.07.003. PMID 18818076. {{cite journal}}: |format= requires |url= (help)

Further reading

Retrieved from "https://en.wikipedia.org/w/index.php?title=TREAT-NMD&oldid=845860628"